DeepMed Research

Henan Cancer Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1977-01-01

Employees: -

Market Cap: -

Website: http://www.anti-cancer.com.cn

Clinical Trials

Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma

Phase 1

Not yet recruiting

Conditions: Peripheral T Cell Lymphoma

Interventions: Drug: SHR0302

First Posted Date: 2023-06-12

Last Posted Date: 2023-06-12

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 30

Registration Number: NCT05900089

Locations: 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China

Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin

Not Applicable

Recruiting

Conditions: Squamous Cell Carcinoma of the Skin

Interventions: Drug: Carrilizumab with albumin-binding paclitaxel

First Posted Date: 2023-06-02

Last Posted Date: 2023-08-08

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 24

Registration Number: NCT05886140

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

Study of SHR-A1811 in HER2-expression Advanced Breast Cancer with Brain Metastases

Phase 2

Recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: SHR-A1811
Drug: Pyrotinib
Drug: Bevacizumab

First Posted Date: 2023-03-15

Last Posted Date: 2024-10-09

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 125

Registration Number: NCT05769010

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

Anrotinib Hydrochloride Combined With Adriamycin for Neoadjuvant Treatment of High-grade Soft Tissue Sarcoma

Not Applicable

Recruiting

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Anrotinib hydrochloride combined with adriamycin

First Posted Date: 2023-02-28

Last Posted Date: 2023-02-28

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 85

Registration Number: NCT05747521

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

Piamprilizumab (AK105) Combined With Radiotherapy for Neoadjuvant Treatment of Soft Tissue Sarcoma

Not Applicable

Recruiting

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Piamprimab (AK105)

First Posted Date: 2023-02-08

Last Posted Date: 2024-02-07

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 31

Registration Number: NCT05718778

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

Hydroxychloroquine Combined With Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer

Phase 2

Not yet recruiting

Conditions: Gemcitabine
Lung Neoplasms
Hydroxychloroquine

Interventions: Drug: Hydroxychloroquine Combined With Gemcitabine

First Posted Date: 2022-12-12

Last Posted Date: 2022-12-12

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 55

Registration Number: NCT05647330

Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy

Phase 1

Not yet recruiting

Conditions: Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited

Interventions: Drug: ThisCART19A
Drug: Fludarabine Pill
Drug: Cyclophosphamide
Drug: VP-16 Protocol

First Posted Date: 2022-12-07

Last Posted Date: 2022-12-07

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 12

Registration Number: NCT05640713

Locations: 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China

Lenvatinib for Advanced Bone and Soft Tissue Sarcoma

Phase 2

Recruiting

Conditions: Effectiveness
Sexuality

Interventions: Drug: Lenvatinib mesylate capsule

First Posted Date: 2022-11-16

Last Posted Date: 2023-08-21

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 60

Registration Number: NCT05617859

Locations: 🇨🇳
Department of Bone and Soft Tissue ,Henan Cancer Hospital, Zhengzhou, Henan, China

Application of Antiosteoporosis Therapy in Osteolysis

Not yet recruiting

Conditions: Complication
Limb; Fusion

Interventions: Other: Anti-osteoporosis therapy

First Posted Date: 2022-11-16

Last Posted Date: 2024-01-18

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 100

Registration Number: NCT05617846

Locations: 🇨🇳
Department of Bone and Soft Tissue ,Henan Cancer Hospital, Zhengzhou, Henan, China

Application of LARS Ligament in Bone Prosthesis Replacement

Not yet recruiting

Conditions: Malignant Tumor

Interventions: Other: LARS ligament and bone prosthesis replacement was performed

First Posted Date: 2022-11-15

Last Posted Date: 2024-01-24

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 100

Registration Number: NCT05616182

Locations: 🇨🇳
Department of Bone and Soft Tissue ,Henan Cancer Hospital, Zhengzhou, Henan, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy